Seroatlas · Human Serome Atlas

VGLL2

Transcription cofactor vestigial-like protein 2

Also known as: VGLL2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N8G2
Gene: VGLL2
Ensembl: ENSG00000170162
Chromosome: 6
Canonical length: 317 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

This gene encodes a protein with a transcriptional enhancer factor 1 (TEF-1) interaction domain. The encoded protein may act as a co-factor of TEF-1 regulated gene expression during skeletal muscle development. Alternatively spliced transcript variants encoding multiple isoforms have been observed. [provided by RefSeq, Jul 2012]

Canonical amino-acid sequenceUniProt

317 residues, UniProt reviewed canonical sequence.

>Q8N8G2|VGLL2
     1  MSCLDVMYQV YGPPQPYFAA AYTPYHQKLA YYSKMQEAQE CNASPSSSGS GSSSFSSQTP
    61  ASIKEEEGSP EKERPPEAEY INSRCVLFTY FQGDISSVVD EHFSRALSQP SSYSPSCTSS
   121  KAPRSSGPWR DCSFPMSQRS FPASFWNSAY QAPVPPPLGS PLATAHSELP FAAADPYSPA
   181  ALHGHLHQGA TEPWHHAHPH HAHPHHPYAL GGALGAQAAP YPRPAAVHEV YAPHFDPRYG
   241  PLLMPAASGR PARLATAPAP APGSPPCELS GKGEPAGAAW AGPGGPFASP SGDVAQGLGL
   301  SVDSARRYSL CGASLLS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VGLL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.69
Highest tissue expression: 121 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 121 nTPM
tongue: 29 nTPM
heart muscle: 5.2 nTPM
esophagus: 0.8 nTPM
hypothalamus: 0.7 nTPM
salivary gland: 0.6 nTPM

Single-cell type

myonuclei: 52 nCPM
thymic myoid cells: 22 nCPM
undifferentiated spermatogonia: 4 nCPM
hofbauer cells: 3.7 nCPM
epididymal basal cells: 1.7 nCPM
fibro-adipogenic progenitors: 1.1 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

hypothalamus: 4.7 nTPM
thalamus: 4.4 nTPM
pons: 1.8 nTPM
medulla oblongata: 1.7 nTPM
midbrain: 1.3 nTPM
spinal cord: 0.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.57
gnomAD pLI: 0.71
gnomAD missense Z: 0.12
DepMap mean gene effect: -0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

transcription coactivator activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VGLL2 as an antibody target. Whether an autoantibody or antibody against VGLL2 could matter depends on whether native VGLL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VGLL2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label VGLL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...